Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

ASXL1 Mutations at Diagnosis Did Not Impact on the Depth of Molecular Response (MR) and on Treatment-Free Remission (TFR) Eligibility in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) Receiving either Nilotinib (NIL) First-Line or Imatinib (IM) with Early Switch to NIL in Case of No Optimal Response in the SUSTRENIM Clinical Trial

Blood (2024) 144 (Supplement 1): 3158.

https://doi.org/10.1182/blood-2024-205465

Published: 2024

Journal Articles

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Blood (2024) 144 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2024-210768

Published: 2024

Journal Articles

Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study

Alfonso Piciocchi, Giovanni Marsili, Ylenia Belperio, Monica Messina, Francesca Paola Paoloni, Stefano Soddu, Isabella Capodanno, Rosaria Sancetta, Elisabetta Abruzzese, Alessandro Pulsoni, Monia Lunghi, Giovanni Caocci, Fausto Castagnetti, Paola Fazi, Marco Vignetti, Massimo Breccia, Fabrizio Pane

Blood (2024) 144 (Supplement 1): 4530.

https://doi.org/10.1182/blood-2024-198366

Published: 2024

Journal Articles

Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax +/- Ibrutinib: Results of the Improve Study

Blood (2023) 142 (Supplement 1): 6521.

https://doi.org/10.1182/blood-2023-174603

Published: 2023

Journal Articles

3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients

Blood (2023) 142 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2023-177619

Published: 2023

Journal Articles

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2023-186406

Published: 2023

Journal Articles

Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL

Blood (2022) 140 (22): 2348–2357.

https://doi.org/10.1182/blood.2022016901

Published: 2022

Includes: Supplemental data

Journal Articles

Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study

Blood (2021) 138 (Supplement 1): 3617.

https://doi.org/10.1182/blood-2021-151538

Published: 2021

Journal Articles

Minimal Residual Disease-Driven Treatment Intensification By Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the Monotherapy and Combination Phases of the Improve Study

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-136507

Published: 2020

Journal Articles

Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML"

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-135972

Published: 2020

Journal Articles

Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group

Gian Matteo Rigolin, Annamaria Frustaci, Alfonso Piciocchi, MS, Andrea Visentin, MDPhD, Orsola Vitagliano, Marta Coscia, MD PhD, Lucia Farina, Gianluca Gaidano, Roberta Murru, MD, Marzia Varettoni, Luca Arcaini, Francesca Cibien, MD, Rossella Paolini, Paolo Sportoletti, MD, Daniela Pietrasanta, MD, Anna Lia Molinari, MD, Francesca M. Quaglia, Luca Laurenti, MD, Roberto Marasca, MD, Monia Marchetti, MD, Annalisa Chiarenza, MD PhD, Francesca Romana Mauro, MD PhD, Omar Perbellini, Donato Mannina, MD, Rosaria Sancetta, MD, Attilio Olivieri, MD, Stefano Molica, MD, Fabrizio Pane, MD, Caterina Patti, MD, Fiorella Iliariucci, Alessandro Gozzetti, Catello Califano, MD, Piero Galieni, Accursio Fabio Augello, MD, Daniele Vallisa, MD, Francesca Cura, Enrico Crea, Paola Fazi, MD, Giulia Zamprogna, MD, Mauro Krampera, MD PhD, Livio Trentin, MD, Felicetto Ferrara, MD, Massimo Gentile, Marco Montillo, Robin Foà, MD, Antonio Cuneo, MD

Blood (2020) 136 (Supplement 1): 23–25.

https://doi.org/10.1182/blood-2020-134669

Published: 2020

Journal Articles

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Simona Soverini, Luana Bavaro, Caterina De Benedittis, Margherita Martelli, Alessandra Iurlo, Nicola Orofino, Simona Sica, Federica Sorà, Francesca Lunghi, Fabio Ciceri, Sara Galimberti, Claudia Baratè, Massimiliano Bonifacio, Luigi Scaffidi, Fausto Castagnetti, Gabriele Gugliotta, Francesco Albano, Antonella Vita Russo Rossi, Fabio Stagno, Francesco di Raimondo, Mariella D’Adda, Eros di Bona, Elisabetta Abruzzese, Gianni Binotto, Rosaria Sancetta, Marzia Salvucci, Isabella Capodanno, Mariella Girasoli, Sabrina Coluzzi, Immacolata Attolico, Caterina Musolino, Elisabetta Calistri, Mario Annunziata, Monica Bocchia, Stefania Stella, Anna Serra, Santa Errichiello, Giuseppe Saglio, Fabrizio Pane, Paolo Vigneri, Flavio Mignone, Maria Antonella Laginestra, Stefano Aldo Pileri, Antonio Percesepe, Elena Tenti, Gianantonio Rosti, Michele Baccarani, Michele Cavo, Giovanni Martinelli

Blood (2020) 135 (8): 534–541.

https://doi.org/10.1182/blood.2019002969

Published: 2020

Includes: Supplemental data

Journal Articles

Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing

Simona Soverini, PhD, Luana Bavaro, Margherita Martelli, Caterina De Benedittis, PhD, Alessandra Iurlo, Nicola Orofino, MD, Livio Pagano, Marianna Criscuolo, Massimiliano Bonifacio, Luigi Scaffidi, MD, Simona Sica, MD, Federica Sorà, MD, Elena Maino, Michela Rondoni, MD, Maria Antonella Laginestra, PhD, Francesca Lunghi, Anna Ermacora, Mariella D'adda, MD, Gabriele Gugliotta, MD PhD, Fausto Castagnetti, Gianantonio Rosti, Cristina Papayannidis, Giovanni Marconi, Antonio Curti, Maria Cristina Miggiano, Sara Galimberti, Antonio Percesepe, MD PhD, Fabio Stagno, Rosaria Sancetta, MD, Mario Annunziata, Franca Falzetti, MD, Isabella Capodanno, Patrizia Pregno, Margherita Maffioli, MD, Tamara Intermesoli, MD, Eros Di Bona, MD, Giovanni Caocci, MD, Imma Attolico, MD, Gianni Binotto, Monica Bocchia, MD PhD, Emanuele Angelucci, MD, Nicola Sgherza, MD, Luigiana Luciano, Flavio Mignone, Stefano A. Pileri, MD PhD, Giovanni Martinelli, Michele Cavo, MD

Blood (2018) 132 (Supplement 1): 789.

https://doi.org/10.1182/blood-2018-99-117166

Published: 2018

Journal Articles

First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response

Blood (2018) 132 (Supplement 1): 4251.

https://doi.org/10.1182/blood-2018-99-110250

Published: 2018

Journal Articles

Health-Related Quality of Life and Symptom Burden in Chronic Myeloid Leukemia Patients Treated with First Line with Imatinib Versus Those Treated with Dasatinib: First Results of the Leonidas Study

Blood (2017) 130 (Supplement 1): 3422.

https://doi.org/10.1182/blood.V130.Suppl_1.3422.3422

Published: 2017

Journal Articles

What's Next in CML - a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening

Simona Soverini, PhD, Luana Bavaro, Caterina De Benedittis, PhD, Margherita Martelli, Stefania Stella, PhD, Paolo Vigneri, MD PhD, Alessandra Iurlo, MD PhD, Nicola Orofino, MD, Simona Sica, MD, Federica Sorà, MD, Sara Galimberti, PhD MD, Claudia Baratè, MD PhD, Francesco Albano, MD, Antonella Russo Rossi, MD, Fabio Ciceri, MD, Francesca Lunghi, MD, Fausto Castagnetti, MD, Gabriele Gugliotta, MD PhD, Gianantonio Rosti, MD, Elena Tenti, PhD, Fabio Stagno, MD PhD, Elisabetta Novella, PhD, Eros Di Bona, MD, Massimiliano Bonifacio, MD, Elisabetta Abruzzese, MD PhD, Marzia Salvucci, MD, Mariella D'Adda, MD, Rosaria Sancetta, MD, Elisabetta Calistri, MD, Monica Bocchia, Isabella Capodanno, MD, Giuseppina Spinosa, MD, Maria Antonella Laginestra, PhD, Santa Errichiello, PhD, Anna Serra, Dr, Francesca Carnuccio, Dr, Sabrina Coluzzi, PhD, Mario Annunziata, MD, Caterina Musolino, MD, Fabrizio Pane, MD, Giuseppe Saglio, MD PhD, Michele Baccarani, MD, Michele Cavo, MD, Giovanni Martinelli, MD

Blood (2017) 130 (Supplement 1): 248.

https://doi.org/10.1182/blood.V130.Suppl_1.248.248

Published: 2017

Journal Articles

The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy

Simona Soverini, Caterina De Benedittis, Stefania Stella, Anna Serra, Francesca Carnuccio, Santa Errichiello, PhD, Luana Bavaro, Fausto Castagnetti, MD, Alessandra Iurlo, MD, Nicola Orofino, MD, Federica Sorà, Simona Sica, Sara Galimberti, MD PhD, Claudia Baratè, Federica Mottadelli, Margherita Martelli, Elisabetta Novella, Eros Di Bona, MD, Giorgina Specchia, Francesco Albano, Elisabetta Abruzzese, MD, Fabio Ciceri, MD, Francesca Lunghi, MD, Carmen Fava, MD, Giovanna Rege Cambrin, MD, Luigia Luciano, Massimo Breccia, MD, Clementina Caracciolo, MD, Marco Santoro, Francesco Di Raimondo, MD, Gabriele Gugliotta, Cristina Papayannidis, MD PhD, Giovanni Cazzaniga, Manuela Mancini, Rosaria Sancetta, Renato Bassan, Caterina Musolino, MD, Giuseppina Spinosa, Silvana Franca Capalbo, Mario Annunziata, MD, Michele Cavo, MD, Gianantonio Rosti, Michele Baccarani, Paolo Vigneri, Giuseppe Saglio, MD, Fabrizio Pane, Giovanni Martinelli

Blood (2016) 128 (22): 3097.

https://doi.org/10.1182/blood.V128.22.3097.3097

Published: 2016

Journal Articles

Blood Cells Dynamic and Thrombo-Haemorragic Events in Low Risk Essential Thrombocytosis Patients. A North Italian and Austrian Study.

Blood (2012) 120 (21): 2839.

https://doi.org/10.1182/blood.V120.21.2839.2839

Published: 2012

Journal Articles

Bendamustine in Chronic Lymphocytic Leukemia (CLL): Outcome According to Different Clinical and Biological Prognostic Factors in Everyday Practice

Francesco Zaja, Michael Mian, Carlo Visco, Cinzia Sissa, Ilaria Nichele, Monica Castelli, Achille Ambrosetti, Simona Puglisi, Renato Fanin, Sergio Cortelazzo, MD, Giovanni Pizzolo, MD, Livio Trentin, MD, Francesco Rodeghiero, Rossella Paolini, Paolo Vivaldi, Rosaria Sancetta, Gianpietro Semenzato

Blood (2012) 120 (21): 3922.

https://doi.org/10.1182/blood.V120.21.3922.3922

Published: 2012

Journal Articles

IHP Interpretation Criteria of Interim-PET Scan Confirms Prognostic Impact In Early Stage Hodgkin Lymphoma Patients without Bulky Disease

Blood (2010) 116 (21): 3890.

https://doi.org/10.1182/blood.V116.21.3890.3890

Published: 2010

NARROW

Myelodysplastic Neoplasms Patients' and Caregivers' Unmet Needs and Their Impact on Their Quality of Life and Symptoms

Evaluating the Impact of Cross-over from Imatinib to Nilotinib on the Overall Survival in Chronic Myeloid Leukemia Using Inverse Probability of Censoring Weighting: Results from the Gimema Sustrenim Study

Outcomes of Venetoclax Retreatment after MRD-Guided Venetoclax +/- Ibrutinib: Results of the Improve Study

3-YEARS and Beyond Study Completion Results of the Otpkima Randomized Clinical Trial in Elderly CML Patients

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL

Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study

Minimal Residual Disease-Driven Treatment Intensification By Sequential Addition of Ibrutinib to Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Results of the Monotherapy and Combination Phases of the Improve Study

Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML"

Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group

Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study

Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing

First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response

Health-Related Quality of Life and Symptom Burden in Chronic Myeloid Leukemia Patients Treated with First Line with Imatinib Versus Those Treated with Dasatinib: First Results of the Leonidas Study

What's Next in CML - a Prospective Study Evaluating Sanger Sequencing and Next Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain (KD) Mutation Screening

The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy

Blood Cells Dynamic and Thrombo-Haemorragic Events in Low Risk Essential Thrombocytosis Patients. A North Italian and Austrian Study.

Bendamustine in Chronic Lymphocytic Leukemia (CLL): Outcome According to Different Clinical and Biological Prognostic Factors in Everyday Practice

IHP Interpretation Criteria of Interim-PET Scan Confirms Prognostic Impact In Early Stage Hodgkin Lymphoma Patients without Bulky Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only